Despite the central role of mTOR in glioma biology, mTORC1 inhibitors, like rapamycin (RAPA) and its analogs (rapalogs), have been shown to have limited efficacy in clinical trials [8], with the exception of RAD001 in pediatric patients affected by subependymal giant-cell astrocytomas (WHO I astrocytomas) [9]. Here, MTOR is linked to astrocytoma (excluding glioblastoma).